Anebulo Pharmaceuticals, Inc.(ANEB)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ANEB Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Anebulo Pharmaceuticals, Inc. (ANEB), a Healthcare sector company. ANEB is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q2 2026), Anebulo Pharmaceuticals, Inc. reports net income of $-2.0M, free cash flow of $-1.3M. Top institutional holders of ANEB by reported 13-F value include 22NW,, Nantahala Capital Management,, MANGROVE PARTNERS IM,, based on the most recent SEC filings. ANEB trades on the Nasdaq exchange and files with the SEC under CIK 1815974. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANEB daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Anebulo Pharmaceuticals, Inc. directly from SEC EDGAR.
Net Income
Q2 2026
$-2.0M
Free Cash Flow
Q2 2026
$-1.3M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-3.5% YoYOperating Income
-11.0% YoYEPS (Diluted)
+21.9% YoYTotal Assets
+198.2% YoYOp. Cash Flow
+21.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Net Income | $-8.5M -3.5% | $-8.2M +30.1% | $-11.7M -71.9% | $-6.8M +77.4% | $-30.3M |
| Operating Income | $-9.2M -11.0% | $-8.3M +29.5% | $-11.8M -72.5% | $-6.8M -89.0% | $-3.6M |
| EPS (Diluted) | $-0.25 +21.9% | $-0.32 +31.9% | $-0.47 -262.1% | $0.29 | — |
| Total Assets | $12.1M +198.2% | $4.1M -65.1% | $11.7M -25.1% | $15.6M -28.1% | $21.7M |
| Operating Cash Flow | $-6.3M +21.5% | $-8.1M +16.4% | $-9.7M -78.1% | $-5.4M -11.6% | $-4.9M |
Get alerted when ANEB's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Anebulo Pharmaceuticals, Inc. including:
Top Institutional Holders of ANEB
22NW, LP
$84.8M15,467,300 shNantahala Capital Management, LLC
$3.1M3,036,325 shMANGROVE PARTNERS IM, LLC
$2.6M2,525,252 shVANGUARD GROUP INC
$440.2K435,821 shMORGAN STANLEY
$403.4K399,404 shGEODE CAPITAL MANAGEMENT, LLC
$162.5K160,760 shRangeley Capital, LLC
$50.5K50,000 shRENAISSANCE TECHNOLOGIES LLC
$25.3K25,098 shCITADEL ADVISORS LLC
$24.5K24,239 shBlackRock, Inc.
$24.0K23,790 sh
| Fund | Value | Shares |
|---|---|---|
| 22NW, LP | $84.8M | 15,467,300 |
| Nantahala Capital Management, LLC | $3.1M | 3,036,325 |
| MANGROVE PARTNERS IM, LLC | $2.6M | 2,525,252 |
| VANGUARD GROUP INC | $440.2K | 435,821 |
| MORGAN STANLEY | $403.4K | 399,404 |
| GEODE CAPITAL MANAGEMENT, LLC | $162.5K | 160,760 |
| Rangeley Capital, LLC | $50.5K | 50,000 |
| RENAISSANCE TECHNOLOGIES LLC | $25.3K | 25,098 |
| CITADEL ADVISORS LLC | $24.5K | 24,239 |
| BlackRock, Inc. | $24.0K | 23,790 |
More Healthcare Companies
View all Healthcare →Put ANEB on your watchlist
Track score changes the day Anebulo Pharmaceuticals, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ANEB a good stock to buy?
13F Pro's AI-powered analysis of Anebulo Pharmaceuticals, Inc. (ANEB) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANEB are available on the ANEB stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ANEB?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANEB. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Anebulo Pharmaceuticals, Inc.'s investment landscape.